New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
12:47 EDTIPSEYIpsen, Galderma increase collaboration for Dysport in new territories
Ipsen and Galderma announced that their collaboration for the promotion and distribution of Dysport, Ipsenís botulinum toxin type A in aesthetic indications, has been extended. Both companies renewed their collaboration in Brazil and Argentina and extended their partnership to Australia where Galderma has the exclusive promotion and distribution rights for Ipsenís Dysport in glabellar lines indication. Both companies also entered into a co-promotion agreement in South Korea where Galderma and Ipsen will co-promote Dysport and Restylane.
News For IPSEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
11:33 EDTIPSEYIpsen announces positive Phase III results for Decapeptyl
Ipsen announced positive results from the phase III study of Decapeptyl administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology 14th Central European Meeting in Cracow, Poland. The primary objective of the study was to assess the efficacy and safety profile of the sustained-release Decapeptyl formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer. This objective was met with castration levels of testosterone achieved in 97.6% of men at week 4 and castration maintained in 96.6% of these men at week 26. The efficacy results and safety profile of Decapeptyl administered by the subcutaneous route are consistent with the known efficacy and safety profile of Decapeptyl administered by the intramuscular route. Based on these results, Ipsen has applied for the addition of the subcutaneous route, alongside the intramuscular route, to the label of Decapeptyl.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use